期刊
SCIENCE ADVANCES
卷 7, 期 49, 页码 -出版社
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/sciadv.abl7682
关键词
-
资金
- National Institutes of Health (NHLBI) [K08HL130557]
- National Institutes of Health (NIAID) [R01 AI159992]
- National Science Foundation [CBET2029361]
- National Institute of Health (NCI) [P30-CA014236]
- National Institute of Health (NIAID) [UC6AI058607]
- DOD/DARPA [HR0011-17-2-0069]
CoVariant-SCAN is a rapid test developed to detect neutralizing antibodies against different SARS-CoV-2 variants, showing consistent results with live virus neutralization assays and aiding in the rapid assessment of antibody response.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants are concerning in the ongoing coronavirus disease 2019 (COVID-19) pandemic. Here, we developed a rapid test, termed CoVariant-SCAN, that detects neutralizing antibodies (nAbs) capable of blocking interactions between the angiotensin-converting enzyme 2 receptor and the spike protein of wild-type (WT) SARS-CoV-2 and three other variants: B.1.1.7, B.1.351, and P.1. Using CoVariant-SCAN, we assessed neutralization/blocking of monoclonal antibodies and plasma from COVID-19-positive and vaccinated individuals. For several monoclonal antibodies and most plasma samples, neutralization against B.1.351 and P.1 variants is diminished relative to WT, while B.1.1.7 is largely cross-neutralized. We also showed that we can rapidly adapt the platform to detect nAbs against an additional variant-B.1.617.2 (Delta)- without reengineering or reoptimizing the assay. Results using CoVariant-SCAN are consistent with live virus neutralization assays and demonstrate that this easy-to-deploy test could be used to rapidly assess nAb response against multiple SARS-CoV-2 variants.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据